7 results on '"Stephanie Marliere"'
Search Results
2. Prognostic impact of coronary microvascular dysfunction in patients with myocardial infarction evaluated by new angiography-derived index of microvascular resistance
- Author
-
Benoit Caullery, Laurent Riou, Stephanie Marliere, Estelle Vautrin, Nicolas Piliero, Olivier Ormerzzano, Helene Bouvaist, Gerald Vanzetto, and Gilles Barone-Rochette
- Subjects
STEMI ,Coronary physiology ,Coronary microvascular dysfunction ,AngioIMR ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: Several methods for measuring IMR derived from angiography have been developed. AngioIMR is a novel method for the assessment of angiography-derived IMR with no requirement for a wire and hyperemia. The prognostic value of AngioIMR is unknown in STEMI patients. We aimed to provide the prognostic value of AngioIMR in patients with ST-elevation myocardial infarction (STEMI). Methods: This study included patients with STEMI who underwent invasive coronary angiography and primary percutaneous coronary intervention (PPCI). AngioIMR was calculated using computational flow and pressure simulation immediately after PPCI. The presence of significant coronary microvascular dysfunction was defined as AngioIMR > 40. The primary outcome was a composite of all cause death or hospitalization for heart failure (MACE). Results: A total of 178 patients were included (65.0 ± 12.8 years on average, 74 % male gender). An AngioIMR > 40 was found in 72 patients. During a median follow-up of 2.9 (2.3–6.9) years, a primary endpoint was observed in 56 patients. By Kaplan-Meier analysis, the risk of MACE was significantly higher in patients with AngioIMR > 40 (log-rank P < 0.01). An Angio IMR > 40 was significantly associated with the occurrence of the primary endpoint in univariate (70 % vs 27 %; hazard ratio 4.519; 95 % CI: 2.550–8.009; p
- Published
- 2025
- Full Text
- View/download PDF
3. Coronary Physiology: Delivering Precision Medicine?
- Author
-
Laura Maitre-Ballesteros, Laurent Riou, Stephanie Marliere, Marjorie Canu, Estelle Vautrin, Nicola Piliero, Oliviez Ormezzano, Helene Bouvaist, Alexis Broisat, Catherine Ghezzi, Daniel Fagret, Gérald Vanzetto, Loïc Djaïleb, and Gilles Barone-Rochette
- Subjects
coronary physiology assessment ,coronary microcirculation dysfunction ,precise medicine ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Coronary physiological assessment is now widely used to assess epicardial coronary lesions in cath lab. Based on clinical evidence, fractional flow reserve (FFR) is the gold standard method to select whether epicardial coronary lesions need revascularization. While additional epicardial indexes, such as instantaneous wave-free ratio (iFR), are also used for revascularization decision-making, several indexes are now also available to explore the coronary microcirculation. Therefore, coronary physiological assessment now allows to explore the entire coronary tree and offer the potential of precision medicine for patients affected by coronary artery disease (CAD). This paper will provide review of the epicardial and microvascular indexes available for the assessment of coronary physiology. More specifically, the already demonstrated contributions of these indexes in the management of CAD and the role they could play in precision medicine will be reviewed with special emphasis on chronic coronary syndrome.
- Published
- 2022
- Full Text
- View/download PDF
4. Stent Underexpansion Is an Underestimated Cause of Intrastent Restenosis: Insights From RESTO Registry
- Author
-
Géraud Souteyrand, Thomas Mouyen, Benjamin Honton, Aurélien Mulliez, Benoit Lattuca, Jean‐Guillaume Dilinger, Sébastien Levesque, Grégoire Range, Nicolas Combaret, Stéphanie Marliere, Ouarda Lamallem, Marine Quillot, Edouard Gerbaud, Pascal Motreff, and Nicolas Amabile
- Subjects
in‐stent restenosis ,optical coherence tomography ,underexpansion ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background Despite improvement in devices, in‐stent restenosis remains a frequent and challenging complication of percutaneous coronary interventions. Methods and Results The RESTO (Morphological Parameters of In‐Stent Restenosis Assessed and Identified by OCT [Optical Coherence Tomography]; study NCT04268875) was a prospective multicenter registry including patients presenting with coronary syndromes related to in‐stent restenosis. All patients underwent preintervention OCT analysis, which led to analysis of in‐stent restenosis phenotype, number of strut layers, and presence of stent underexpansion. The primary end point was the in‐stent restenosis type according to the OCT morphological classification. The 1‐year incidence of target vessel failure (a composite of death from cardiac causes, target‐vessel myocardial infarction, or ischemia‐driven target‐vessel revascularization) was assessed. The study included 297 patients. The culprit stent was a drug‐eluting stent in 74.2% of cases. OCT analysis revealed the presence of neoatherosclerosis in 57% (52% calcified), neointimal hyperplasia in 43% (58% homogeneous), stent underexpansion (minimal stent area
- Published
- 2024
- Full Text
- View/download PDF
5. Coronary Physiology: Delivering Precision Medicine?
- Author
-
Gilles Barone-Rochette, Loïc Djaïleb, Gérald Vanzetto, Daniel Fagret, Catherine Ghezzi, Alexis Broisat, Helene Bouvaist, Oliviez Ormezzano, Nicola Piliero, Estelle Vautrin, Marjorie Canu, Stephanie Marliere, Laurent Riou, and Laura Maitre-Ballesteros
- Subjects
General Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2022
- Full Text
- View/download PDF
6. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry
- Author
-
Jacques, Machecourt, Nicolas, Danchin, Jean Marc, Lablanche, Jean Marie, Fauvel, Jean Louis, Bonnet, Stephanie, Marliere, Alison, Foote, Jean Louis, Quesada, Hélène, Eltchaninoff, and Gérald, Vanzetto
- Subjects
Male ,Sirolimus ,Antibiotics, Antineoplastic ,Coronary Disease ,Thrombosis ,Middle Aged ,Disease-Free Survival ,Blood Vessel Prosthesis Implantation ,Drug Delivery Systems ,Treatment Outcome ,Risk Factors ,Case-Control Studies ,Humans ,Insulin ,Female ,Stents ,Prospective Studies ,Registries ,Angioplasty, Balloon, Coronary ,Diabetic Angiopathies ,Aged - Abstract
We sought to assess the frequency and causes of stent thrombosis in diabetic and nondiabetic patients after implantation of sirolimus-eluting stents.Safety concerns about late stent thrombosis have been raised, particularly when drug-eluting stents are used in less highly selected patients than in randomized trials.The EVASTENT study is a matched multicenter cohort registry of 1,731 patients undergoing revascularization exclusively with sirolimus stents; for each diabetic patient included (stratified as single- or multiple-vessel disease), a nondiabetic patient was subsequently included. Patients were treated with aspirin + clopidogrel for at least 3 months and were followed for 465 (range 0 to 1,062) days (1-year follow-up in 98.5%). The primary end point was a composite of stent thrombosis (according to Academic Research Consortium definitions), cardiovascular death, and nonfatal myocardial infarction (major adverse cardiac events [MACE]).During follow-up, MACE occurred in 78 patients (4.5%), cardiac death in 35 (2.1%), and stent thrombosis in 45 (2.6%): 30 definite, 23 subacute, and 22 late, including 9 at6 months. In univariate analysis, the 1-year stent thrombosis rate was 1.8 times higher in diabetic than in nondiabetic patients (3.2% vs. 1.7%; log rank p = 0.03), with diabetic patients with multiple-vessel disease experiencing the highest rate and nondiabetic single-vessel disease patients the lowest (4.3% vs. 0.8%; p0.001). In multivariate analysis, in addition to the interruption of antithrombotic treatment, independent stent thrombosis predictors were previous stroke, renal failure, lower ejection fraction, calcified lesion, length stented, and insulin-requiring diabetes.The risk of sirolimus stent thrombosis is higher for multiple-vessel disease diabetic patients.
- Published
- 2006
7. Prognostic significance of severe coronary microvascular dysfunction post-PCI in patients with STEMI: A systematic review and meta-analysis.
- Author
-
Marjorie Canu, Charles Khouri, Stéphanie Marliere, Estelle Vautrin, Nicolas Piliero, Olivier Ormezzano, Bernard Bertrand, Hélène Bouvaist, Laurent Riou, Loic Djaileb, Clémence Charlon, Gerald Vanzetto, Matthieu Roustit, and Gilles Barone-Rochette
- Subjects
Medicine ,Science - Abstract
Coronary microvascular dysfunction (CMVD) is common and associated with poorer outcomes in patients with ST Segment Elevation Myocardial Infarction (STEMI). The index of microcirculatory resistance (IMR) and the index of hyperemic microvascular resistance (HMR) are both invasive indexes of microvascular resistance proposed for the diagnosis of severe CMVD after primary percutaneous coronary intervention (pPCI). However, these indexes are not routinely assessed in STEMI patients. Our main objective was to clarify the association between IMR or HMR and long-term major adverse cardiovascular events (MACE), through a systematic review and meta-analysis of observational studies. We searched Medline, PubMed, and Google Scholar for studies published in English until December 2020. The primary outcome was a composite of cardiovascular death, non-cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and rehospitalization for heart failure occurring after at least 6 months following CMVD assessment. We identified 6 studies, reporting outcomes in 1094 patients (mean age 59.7 ± 11.4 years; 18.2% of patients were women) followed-up from 6 months to 7 years. Severe CMVD, defined as IMR > 40 mmHg or HMR > 3mmHg/cm/sec was associated with MACE with a pooled HR of 3.42 [2.45; 4.79]. Severe CMVD is associated with an increased risk of long-term adverse cardiovascular events in patients with STEMI. Our results suggest that IMR and HMR are useful for the early identification of severe CMVD in patients with STEMI after PCI, and represent powerful prognostic assessments as well as new therapeutic targets for clinical intervention.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.